Some of the information regarding this project is accessible to members only. If you are a member of MabNet, please contact Ms. Sarah Chan or Dr. Butler to sign up for this website.
We apologize for not being able to grant you membership if you are not a member of MabNet.
Our mission is to develop a large-scale production process for single glycoform monoclonal antibodies (Mabs) for therapeutic applications. There has been a rapid increase in demand for production of clinically-approved bio-pharmaceuticals for the treatment of human diseases. Monoclonal antibodies have dominated the bio-pharmaceutical markets with around 20 presently marketed, and over 200 in various stages of clinical trials. The estimated global sales of Mabs have increased from $300 million in 1997, to $25 billion in 2007 (Repligen annual report, 2008).